+63%1
PC-IOL unit sell-out
2024–2025
While total unit sell-out in the same recorded IOL portfolio grew 3%.
For cataract & RLE clinics and IOL companies
Premium IOL growth below expectations?
Find what’s holding it back—and change it with your team.
I help clinics improve premium conversion and IOL companies build sustained adoption. We identify the barriers, redesign the patient pathway and work with your team to implement and measure the changes.
Built around how patients decide.
Oleksii SologubStrategic Advisor in Premium IOL Adoption
Hands-on IOL business experience since 1996, direct patient insight and personal involvement in implementation.
Where do you need progress?
A Clear Business Problem. A Practical Way Forward.
Start with the change your business needs. The diagnosis determines the work—not a preselected tool or training session.
For clinics
Patients are interested. Too few move forward.
Options are explained differently. Patients leave unsure. Training happened, but daily practice did not change.
Improve premium conversion by finding avoidable gaps in the pathway and helping the team change how it works.
Improve your clinic's premium pathwayFor IOL companies
The launch got attention. Routine use hasn’t followed.
First orders do not become repeat use. Product differentiation gets lost. A successful pilot has not become a market approach.
Identify what is limiting adoption of your product, test the changes with clinics and decide what deserves wider rollout.
Build sustained product adoptionBuilding a new premium service or preparing a lens launch? We can design the pathway and measurement plan before rollout.
Documented commercial experience
An Operating Record Behind the Advice
These figures come from the ophthalmic distribution business I co-founded and chair. They show premium-IOL purchasing growth across one market in 2024–2025—not a forecast for your clinic or a controlled test of PDDA®.1
3 in 41
Active partner accounts purchased PC-IOLs
2025
Breadth across the active partner network.
+59%1
PC-IOL volume across repeat accounts
2024–2025
Higher recorded PC-IOL purchasing among accounts purchasing in both years.
+40%1
More routine PC-IOL accounts
2024–2025
The number purchasing in at least six months grew 40%.
PC-IOL means presbyopia-correcting IOL. Figures are distributor sell-out — not implantations, clinical outcomes or national market share. Repeat accounts recorded positive annual net PC-IOL sell-out in both years; routine accounts did so in at least six calendar months of a year.
What the work is designed to change
A Better Pathway. A Team That Can Carry It Forward.
The business objective is better conversion or sustained adoption. These are the practical changes we work on and measure—not promises of a guaranteed uplift.
01
Know which barrier deserves investment.
Replace competing assumptions with a prioritised diagnosis. Check the offer, patient understanding, access and workflow before committing to more training or marketing.
02
Make good practice easier to repeat.
Patients get clearer preparation and handoffs. Staff know the agreed actions and who owns them. Your team receives usable tools, practice and implementation support.
03
Know what changed—and what to do next.
Compare the agreed baseline with follow-up. Distinguish use of the new process from commercial results, then decide what to keep, revise or scale.
The handover includes a prioritised plan, patient-facing and team tools, named responsibilities and a measurement review. Clinical suitability, patient preferences and affordability remain part of every decision.
Why work with me
The Business of IOLs. The Reality of Patient Decisions.
I bring both into the same project—and stay involved as your team puts the changes to work.
Hands-on ophthalmic business experience
In ophthalmology since 1996: equipment, application support, business-building and premium-IOL market development. I know that a training session, a first order and routine use are different milestones.
Learning from patients, not only about them
Direct conversations, patient-education channels, IOL questionnaires and analysis of public discussions show the questions professionals may not hear in the room. I use those observations to form better questions for your market—not assume that every patient thinks alike.
22,700+ questionnaire records · 65+ countries and territories · 15M+ verified views across two educational channels
Implementation with your team
I lead diagnosis and design personally. Your named implementation lead owns day-to-day use, with agreed team training, review and support. The aim is work your people can carry forward.
How the work connects
PDDA® Is the Method Behind the Programme
Patient Decision Design Architecture connects business strategy, patient decisions and team implementation.
First Mile → Clinic Handoff → Last Mile → Outcome Loop
Smart Values™ connects product value with patient priorities. Smart Promise™ aligns what the clinic promises with what its team delivers. Smart Sight™ structures the conversation around priorities, options and trade-offs.
Easy Lens Selector™ is one supporting tool inside Smart Sight™, not the whole programme. The diagnosis determines which parts of PDDA® your project needs.
Insights
Strategic Insights
Analysis and field observations on premium IOL adoption, patient decision design, clinic strategy and the last mile of clinical value.
Start the conversation
What Would Better Premium Performance Look Like for You?
In a 20-minute introductory call, we’ll clarify the result you want, what you’ve already tried and whether a focused project makes sense. Detailed diagnosis and implementation are scoped separately.